Biocon says use of Itolizumab in COVID-19 treatment encouraging

Biocon has witnessed encouraging results in the use of its novel biologic Itolizumab for treating some Covid-19 related conditions, the pharmaceutical company said on Friday. Biocon said the first set of trials using the drug were done in Mumbai and Delhi.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news